Professor Marc-Emmanuel Dumas, PhD MEng MSc BEng BSc FRSB FRSC
Marc-Emmanuel Dumas is Chair in Systems Medicine, a joint appointment between the Department of Metabolism, Digestion and Reproduction's section of Biomolecular Medicine and the National Heart and Lung Institute's section of Genomic and Environmental Medicine.
Professor Dumas is head of the Section of Biomolecular Medicine, which hosts state-of-the-art equipment dedicated to metabolomics, crystallisation science and tissue culture.
Professor Dumas is also the founding director of Imperial's Microbiome Network, a cross-faculty multidisciplinary network of excellence made of >60 PIs and their groups to consolidate research, teaching and public engagement activities around the microbiome.
Professor Dumas develops novel research avenues in the field of metabolomics, microbiomics in systems medicine, targeting mostly the role of the microbiome (but not limited to) in metabolic and cardiorespiratory diseases as well as in chronic inflammation (including neuroinflammation) and certain types of cancers.
Professor Dumas currently holds an Adjunct Professorship at McGill University's Genome Innovation Centre and Department of Human Genetics in Montréal, Canada, and an open-ended appointment as CNRS principal investigator in France.
Prior to this, he was appointed at Imperial as Lecturer (2009-2013), Senior Lecturer (2013-2015) and Reader (2015-2018). He took his CNRS position at Ecole Normale Supérieure de Lyon in 2007, where he started a metabolomics and systems biology group and was awarded a Young Investigator Award from the Agence Nationale de la Recherche.
He studied in France and qualified as an Engineer in Agronomy (MEng, Ingénieur Agronome) in 1998 with two MSc in "Biochemistry & Genetics" and "Applied Physiology", before being awarded a PhD in "Biochemistry, Molecular and Cell Biology" in 2002 and joining Imperial to coordinate the metabolomics team of the Wellcome Trust-funded Biological Atlas of Insulin Resistance consortium (BAIR), where he led pioneering research on the role of microbial metabolites in non-alcoholic fatty liver disease, insulin resistance and type 2 diabetes.
Membership of Societies
- Fellow of The Royal Society of Biology, elected in 2019
- Fellow of The Royal Society of Chemistry, elected in 2017
- Member of The British Toxicology Society
- The Metabolomics Society, member
- The Metabolic Profiling Forum, member and conference chair of Metabomeeting 2008 in Lyon, France, organised by the MPF.
Committees and Editorships
Professor Dumas is an Editor of Scientific Reports (Nature Publishing Group), Acta Diabetologica and was a member of the editorial board for the Journal of Proteome Research (American Chemical Association, 2009-2013).
He is an international member of the grant award committee for the French national research council Agence Nationale de la Recherche (ANR) and a reviewer for the H-2020 European framework programme.
Awards and funding
Professor Dumas' lab recent funding includes by EU, MRC, Guts UK, Diabetes UK, Advance charity and the Academy of Medical Sciences grants. Recent grants include for instance:
- NEW: ADVANCE Charity. Metabolomic and proteomic markers of traumatic injury, cardiometabolic risking premature aging, 2021-2024 (PI)
- UKRI: UK Coronavirus Immunology Consortium, 2020-2021 (CoI)
- Diabetes UK: Causality Assessment of the Gut-Liver Axis in insulin Resistance, 2020-2023 (PI)
- Academy of Medical Sciences: Metabolomics and Precision Medicine for Myocardial Recovery, (starter grant to Dr. Brian Halliday, 2019-2021)
- Guts UK: Precision Medicine Through Integrative Metagenomics and Phenomics in Human Non-Alcoholic Fatty Liver Disease, 2019-2021 (PI)
- ERANET(MRC/ANR/BMBF/MINECO): The Gut Microbiome in Neuroinflammation and Neurodevelopmental Disorders (µNeuroInf) 2015-2018 (Coordinator, total award €1.1M).
- EC-FP7: Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases (MetaCardis) 2012-2018 (total award €12M, PI for Imperial €1.2M)
- The Royal Society - CNRS: Metabonomics of Fragile X Syndrome "MetabonomiX"
- Institut Mérieux: Signalling Metabolites, 2010-2013 (sole PI €150K)
- EC-FP7: European large-scale functional genomics in the rat for translational research (CoI, Euratrans: http://www.euratrans.eu/ 2010-2015)
- Young Investigator Award, Agence Nationale de la Recherche, 2007 (€150K)
- Several ANR grants (mQTL, SysBioX, 2007-2011), France (total €1M)
Prof. Dumas’ research interests in systems medicine include metabolomics, quantitative genetics, metagenomics and network biology, more specifically integration of metabolomic data with other "omics" (transcriptomics, proteomics, genome polymorphism and metagenomics) to identify metabolites and genes associated with metabolic and cardiorespiratory pathologies, ie insulin resistance, metabolic syndrome, type 2 diabetes, obesity, asthma, dyslipidemia, atherosclerosis, hypertension, non-alcoholic fatty liver disease, but also ageing and cancer. This functional integration of "omics" sciences identifies candidate drug targets for mechanistic validation.
Prof. Dumas’ contribution to insulin resistance research was the identification of a gut microbiota – related metabolic phenotype (or “metabotype”) in non-alcoholic fatty liver disease. Methylamines (monomethylamine, dimethylamine, trimethylamine and trimethylamine-N-oxide), a class of microbial metabolites derived from dietary choline-containing compounds, are associated with the development of insulin resistance, and more specifically non-alcoholic fatty liver disease. This observation on gut microbial metabolism brought an independent confirmation of several previous findings in metagenomic projects from a metabolic point of view. Methylamines are now thought to be involved in other insulin resistance related pathologies such as atherosclerosis.
In terms of systems biology modeling, Prof. Dumas is one of the pioneers in the field of Metabotype Quantitative Trait Locus (mQTL) Mapping and Metabolome-wide Genome-Wide Association Studies (i.e., metabolomic GWAS), by integrating genome-wide polymorphisms with metabolome-wide quantitative variation. Dr. Dumas now develops the concept of microbiome-wide metabolome-wide association studies (MW2AS), combining High-Throughput Sequencing and Metabolic Profiling technologies. Prof. Dumas has also developed a keen interest in knowledge visualization and integration of metabolic signatures with protein-protein interaction networks (interactome), and recently introduced a new approach to understand the regulation of metabolic patterns, by mapping metabolic networks onto protein-protein interaction networks: integrated metabolome and interactome mapping (iMIM).
Prof. Dumas introduced the concept of "Metabolomics-on-a-chip", i.e. the hyphenation of bioartificial organs based on microfluidic biochips with metabolic profiling technologies, and pioneered applications for in vitro predictive systems toxicology and pharmacology.
- "Biological signatures", 2002.
- "Metabolomics-on-a-chip", 2011.
- 3 patents filed in Dec''12.
Professor Dumas is Director of E-Learning for the Division of Systems Medicine. He teaches in several internal and external courses at Imperial College London, including:
Undergraduate Medicine MBBS/BSc 6-yr course
Core examiner and lecturer for the MRes in Biomedical Research.
Imperial International Phenome Training Centre's external short courses.
et al., 2021, A prenylated dsRNA sensor protects against severe COVID-19., Science, Vol:374
et al., 2021, Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study, The Lancet, Vol:398, ISSN:0140-6736, Pages:223-237
et al., 2021, Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health., Gut, Vol:70, ISSN:0017-5749, Pages:2105-2114
et al., 2020, Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology, Nature Communications, Vol:11, ISSN:2041-1723
et al., 2020, Statin therapy is associated with lower prevalence of gut microbiota dysbiosis, Nature, Vol:581, ISSN:0028-0836, Pages:310-+
et al., 2018, Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women., Nat Med, Vol:24, Pages:1070-1080
et al., 2018, Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota, Microbiome, Vol:6, ISSN:2049-2618
et al., 2017, A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nature Medicine, Vol:23, ISSN:1546-170X, Pages:107-113
et al., 2015, Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome, Cell Metabolism, Vol:22, ISSN:1932-7420, Pages:320-331
et al., 2014, Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the Xenobiotic sensor PXR and toll-like receptor 4, Immunity, Vol:41, ISSN:1074-7613, Pages:296-310
Dumas M-E, Kinross J, Nicholson JK, 2014, Metabolic Phenotyping and Systems Biology Approaches to Understanding Metabolic Syndrome and Fatty Liver Disease, Gastroenterology, Vol:146, ISSN:0016-5085, Pages:46-62
et al., 2007, Metabotyping of Caenorhabditis elegans reveals latent phenotypes, Proceedings of the National Academy of Sciences of the United States of America, Vol:104, ISSN:0027-8424, Pages:19808-19812
et al., 2007, Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models, Nature Genetics, Vol:39, ISSN:1061-4036, Pages:666-672
et al., 2006, Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice, Proceedings of the National Academy of Sciences of the United States of America, Vol:103, ISSN:0027-8424, Pages:12511-12516